INTERIM REPORT JANUARY SEPTEMBER 2017
|
|
- Imogen Moore
- 5 years ago
- Views:
Transcription
1 INTERIM REPORT JANUARY SEPTEMBER 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN Octber 27, 2017 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap): XVIVO
2 HIGHLIGHTS 2017-Q3 First patient Heart transplanted using the new machine and slutin Inclusin f all patients in NOVEL study cmpleted Basis fr PMA applicatin Inclusin f all patients in PrimECC study cmpleted 20 patients included in Liver study with STEEN Slutin n DBD livers Clean rm in Lund increased prductin and R&D capability January September 2017 Interim reprt presentatin 2
3 SALES HIGHLIGHTS 2017 JAN - SEP DOUBLE DIGIT GROWTH FOR NON-DURABLE SALES Sales: - Nn-durable gds +15%* r 102 MSEK Net sales in SEK millins (Rlling 12 mnths) Warm perfusin Cld preservatin Freight and ther EU & Aus: 2 new cuntries with XPS - Australia & the Netherlands - Cntinued high interest frm custmers fr the XPS & LS USA - XPS cntract signed with clinic in Kentucky and cntinued high interest frm new clinics * Lcal currency grwth fr nn-durable gds +13% YTD and +11% Q3 January September 2017 Interim reprt presentatin 3
4 PROFIT & LOSS Sales nn-durable +15% Cntinued strng grss margin Custmer supprt build up Jan Sep Jan Dec (SEK millins) Net sales Net sales nn-durable gds Grss prfit Grss Margin % 76% 74% 74% Grss Margin nn-durable gds % 79% 80% 80% Selling expenses excl. items aff. cmp% -31% -24% -24% Admin. expenses excl. items aff. cmp%* -13% -12% -12% R&D exp. excl. Amrt. & items aff. cmp%* -19% -18% -19% Items affecting cmparability* -2% -7% -8% R&D Amrtizatin %* -7% -8% -7% Other incme/expenses % -2% -2% -2% Operating Result % 2% 3% 2% Running business prfitable despite high investments in Marketing and R&D EBITDA excl. items eff. cmp.* EBITDA excl. items eff. cmp% 15% 20% 19% EBITDA EBITDA % % % % * Items affecting cmparability: 2017 Jan-Sep 2.3 (7.3) MSEK. R&D Amrtizatin : 2017 Jan-Sep 7.9 (7.7) MSEK. January September 2017 Interim reprt presentatin 4
5 PRODUCTS & MARKETS FOR FUTURE GROWTH
6 XVIVO - FUTURE GROWTH OPPORTUNITIES Expansin f Lung transplantatin indicatin, e.g. Infectin (e.g. Hep C) EVLP treatment, Increase f DCD lungs Heart Transplant prject, early clinical phase STEEN Slutin fr Liver Transplant, clinical phase ITT* - Drug administratin t islated rgans (e.g. Cancer) with STEEN Slutin, early clinical phase PrimECC imprve clinical prf, clinical phase * ITT r Islated Tissue Therapy is a therapy where ne part f he bdy is islated fr treatment in rder t avid side effects. January September 2017 Interim reprt presentatin 6
7 LUNG TRANSPLANTATION XPS & STEEN Slutin nly FDA (HDE) apprved device fr warm perfusin f lungs NOVEL study inclusin finalized: patients - Fllw-up 1 year - Frm basis fr PMA applicatin, study dcumentatin & mnitring and analysis nging - Dialgue with FDA nging PAS (Pst Apprval Study) - 5 patients until inclusin cmplete - Fllw-up 3 years Restrictins n patients and recipients will be remved when PAS inclusin finalized January September 2017 Interim reprt presentatin 7
8 LUNG TRANSPLANTATION Next steps fr lung warm perfusin (EVLP) XVIVO will cntinue t clinically develp EVLP: DCD transplantatin (Dnatin after Circulatry Death) cntrlled / uncntrlled Infectin therapy thrugh EVLP, e.g. Pneumnia therapy and virus reductin Hep C study: 2 patients included Investigate immunlgical respnse with EVLP targeting shrt- & lng-term survival New markers and parameters fr imprved evaluatin safer decisin making January September 2017 Interim reprt presentatin 8
9 XVIVO - HEART TRANSPLANTATION Heart perfusin and preservatin slutin and device develped by Prf. Steen First clinical trial started with new technlgy: First patient transplanted with the new device (new slutin and new machine) Prf f cncept study with 6 patients Pre-clinical prcine prf f cncept studies indicate: Avidance f ischemic time Better heart quality Lnger preservatin time (24h) pssible Mycardium tests cmparing perfused and nnperfused hearts. Heart Tx very gd fit with XVIVO XVIVO experience frm Lung device develpment Synergies in develpment, regulatry and M&S Many f the same clinics and KOLs make Heart and Lung Tx January September 2017 Interim reprt presentatin 9
10 PRIMECC Tailr made priming slutin aiming at imprving patients cnditin after having undergne pen-heart surgery with a heart-lung machine PRIMECC develped t avid side-effects when priming heart-lung machines. Schematic drawing f heart with heart-lung machine > pen heart surgeries every year in the USA alne. Estimated ~1 millin in the wrld / year. N FDA apprved prduct fr indicatin. Previus perfrmed clinical prf f cncept study shwed interesting results. Patent granted in EU, USA China and Japan. CE marked Class III Medical Device. January September 2017 Interim reprt presentatin 10
11 PRIMECC STUDY INCLUSION FINALIZED patients Sahlgrenska Univ. hsp. - randmized, cntrlled, blinded Aim t increase clinical dcumentatin fr PrimECC avidance f side-effects Results estimated t be analyzed & published during Q / Q EU & US multi-center studies planned t start after supprting clinical trial results are available January September 2017 Interim reprt presentatin 11
12 SUMMARY OTHER NEW INDICATIONS Liver transplantatin: Results n 20 patients in first clinical STEEN Slutin Liver study shw gd clinical results Marginal (DCD) Liver study planned t start in Canada n 2 centers Islated Tissue Therapy - Cancer Prf f cncept study perfusing lungs in viv fr treatment f cancer is nging 2nd patient successfully treated January September 2017 Interim reprt presentatin 12
13 OUTLOOK Q & FOCUS AREAS Thracic Surgery Lungs - Cntinue t increase ftprint and use f EVLP technlgy Lungs - PMA applicatin and submissin Lungs - Reinfrced clinical develpment f EVLP, especially in the US Heart - Accelerating Heart transplant clinical prgram PrimECC - Analysis f PrimECC clinical data and cntinued clinical prgram New indicatins Liver - STEEN Slutin clinical develpment fr DCD & marginal Livers ITT - Islated tissue therapy (STEEN Slutin IVLP: Cancer, Limb perfusin) Kidney cntinued pre-clinical studies with STEEN Slutin January September 2017 Interim reprt presentatin 13
14 Strategic gals Slidify psitin in Thracic surgery - Lungs + Heart Build new business using STEEN Slutin tech. in ther indicatins January September 2017 Interim reprt presentatin 14
15 XVIVO PERFUSION Patients die waiting fr an rgan transplant XVIVO has a Patented, Apprved and Dcumented technlgy t make mre rgans available fr the benefit f patients XVIVO has the experience, capability, cmpetence and technlgy t expand int mre indicatins/markets
REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE
REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN February 12, 2018 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap): XVIVO HIGHLIGHTS
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationPress Release. Adocia: Activity and results for the first half of 2013
Press Release Adcia: Activity and results fr the first half f 2013 Intensificatin f R&D activity ahead f the launch f three clinical trials fr insulin prjects, starting in the secnd half f 2013 Net result
More informationRate Lock Policy. Contents
Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram
More informationTaking a nano-based medical product to the international market
Cmmercialisatin f nanmaterials: prcess, issues, and management June 7, 2017 Taking a nan-based medical prduct t the internatinal market The Unmet Need The glbal incidence f breast cancer is 1.7m annually
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationActivating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain
More informationNovel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.
Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More informationActivating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains
More informationEvaluation of Hunter & New England HealthPathways
Evaluatin f Hunter & New England HealthPathways 2 General Practice & Ambulatry Care Activity General Practice MBS data: In 2013 there were 3.3 millin patient attendances t 730 GPs in the HML regin, a 5.6%
More informationARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST
ARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST 7 th July 2017 Cntent 1 Intrductin 2 Tpics fr EOI in the 4 th call 3 The applicatin prcess and imprtant dates 4 Guideline fr EOIs Deadline
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationIndependent Charitable Patient Assistance Program (IPAP) Code of Ethics
Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationThe Cannabis Act and Regulations
The and Regulatins OVERVIEW The and Regulatins cme int frce n Octber 17, 2018 and replaces the Access t Cannabis fr Medical Purpses Regulatins (ACMPR), and any mentin f Cannabis and Marihuana in the Narctics
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationAppendix C. Master of Public Health. Practicum Guidelines
Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum
More informationAmniotic Membrane Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Amnitic Membrane Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal amnitic membrane market size was valued at USD 2.26 billin in 2017 and is estimated
More informationAction plan: serialisation of Nordic packages focus on Product Codes
19.6.2017, versin 5 Actin plan: serialisatin f Nrdic packages fcus n Prduct Cdes The aim f this dcument is t help pharma cmpanies t prepare fr prduct cde changes and t be able t maintain prduct cdes in
More informationMeeting Minutes. III. New Business (Slide Presentation is embedded for reference) [slides 3-47] May 2011 DMRAB Presentation PUBLIC C
Cmmnwealth f Kentucky Cabinet fr Health and Family Services Department fr Medicaid Services Drug Management Review Advisry Bard Meeting May 12, 2011 Meeting Minutes Vting Members in attendance: Kim Crley,
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationHSC 106 Personal Health Plan for Learning Activities & Assessment linked to Michigan Teacher Preparation Standards
HSC 106 Persnal Health Plan fr Learning Activities & Assessment linked t Michigan Teacher Preparatin Standards Standard 1 Cmpetency 1.1 Understand basic health cntent as it relates t schl health educatin.
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationTO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council:
CORPORATE REPORT NO: R049 COUNCIL DATE: March 12, 2018 REGULAR COUNCIL TO: Mayr & Cuncil DATE: March 8, 2018 FROM: SUBJECT: General Manager, Planning & Develpment City Slicitr, Legal Services Cannabis
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationPress Release. Adocia Reports Operational and Financial Results for the First Half of 2014
Press Release Adcia Reprts Operatinal and Financial Results fr the First Half f 2014 Majr clinical results reprted n tw frmulatins based n insulin Sund financial psitin with apprximately EUR 16 millin
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationHarold P. Adams, Jr., MD Department of Neurology Carver College of Medicine UIHC Comprehensive Stroke Center University of Iowa
Harld P. Adams, Jr., MD Department f Neurlgy Carver Cllege f Medicine UIHC Cmprehensive Strke Center University f Iwa D nt receive persnal cmpensatin frm cmmercial interests D receive grant supprt frm
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationPhotomedicine Devices And Technologies Market Size, Share & Trends Analysis Report and Segment Forecast, 2024 Grand View Research, Inc
Phtmedicine Devices And Technlgies Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2024 Grand View Research, Inc The glbal phtmedicine devices and technlgies market accunted fr USD 314.9
More informationWCPT awards programme 2015
WCPT awards prgramme 2015 The WCPT awards prgramme recgnises utstanding cntributins and leadership by individual physical therapists and grups t the prfessin and/r glbal health at an internatinal level.
More informationThe effects of a two-school. school-year. back education program. in elementary schoolchildren
IEA Maastricht - 12 July 2006 The effects f a tw-schl schl-year multi-factrial back educatin prgram in elementary schlchildren Drs Elisabeth Geldhf Prf Dr D De Clercq Prf Dr I De Burdeaudhuij Prf Dr G
More informationAncillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community.
Ancillary Sympsia Request fr Prpsals Partnerr with the Endcrine Sciety t Educate the Endcrine Cmmunity. Jin the Endcrine Sciety in Bstn fr the 98 th Annual Meeting & Exp frm April 1 4, 2016. ENDO 2016
More informationCode of Conduct for Employees
Crprate Human Resurces Plicy Cntent Updated: 2016-06-22 Wrk Envirnment Plicy N: HR-01-09 Page 1 f 5 Apprval: 2014-09-24 Cde f Cnduct fr Emplyees POLICY STATEMENT The residents and businesses f the City
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationOxford Immunotec Company Overview
Oxfrd Immuntec Cmpany Overview J.P. Mrgan Healthcare Cnference 2019 Oxfrd Immuntec Glbal PLC 94C Innvatin Drive Miltn Park, Abingdn Oxfrdshire, OX14 4RZ, United Kingdm Cmpany Number 08654254 www.xfrdimmuntec.cm
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationCenter for Circulatory Support. The Center for Circulatory Support strives for continuous improvement in quality and patient outcomes
Palliative Care Cnsults: Centers fr Medicare and Medicaid Services Decisin Mem fr Ventricular Assist Devices fr Bridge-t-Transplant and Destinatin Therapy Center fr Circulatry Supprt The Center fr Circulatry
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationActivating the immune system to fight cancer
Activating the immune system t fight cancer RedEye pre-asco seminar Erik Digman Wiklund, CFO 28 May 2018 Frm a sequential treatment strategy directly targeting the cancer 1 Surgery When pssible, surgical
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More informationJessica Philpott MD PhD Digestive Diseases Institute Cleveland Clinic
Jessica Philptt MD PhD Digestive Diseases Institute Cleveland Clinic Objectives Review the Crhn s and Clitis Fundatin Challenges t Research Gals 2018 Review data in envirnment and genetics as cntributing
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationA. Catalonia World Health Organization Demonstration Project
A. Catalnia Wrld Health Organizatin Demnstratin Prject In 1989, the Health Department f Catalnia (Spain) and the Cancer Unit at the WHO (Geneva) designed and planned a demnstratin prject fr implementatin
More informationFinding the right 90 people in 90 days and what to do with them:
Finding the right 90 peple in 90 days and what t d with them: Wh can yu give the 3 packets (with instructins) t? Current Preferred Custmers nt currently n the Daily Essentials Packets. Friends and Family
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationBritish Sign Language (BSL) Plan October 2018 Scottish Charity Regulator
British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public
More informationCONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW
FACT SHEET CONTACT: Amber Hamiltn 212-266-0062 TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW Type 2 diabetes accunts fr 90-95% f the 29.1 millin diabetes cases in the U.S. 1 Obesity is a majr independent
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationSUNMIiRK UN GLOBAL COMPACT COMMUNICATION ON PROGRESS. Arcon-Sunmark A/S Skørping Nord 3 DK-9520 Skørping CVR:
SUNMIiRK Arcn-Sunmark A/S Skørping Nrd 3 DK-9520 Skørping CVR: 10778530 Tel. +45 9839 1477 mailarcn-sunmark.cm UN GLOBAL COMPACT COMMUNICATION ON PROGRESS FEBRUARY 2017 CONTENTS Statement f Cntinued Supprt
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More informationRadiographic Procedures I Laboratory. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: RAD 61C Radigraphic Prcedures I Labratry Technlgy and Health Divisin
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationPracticum Evaluation Form - Formative Assessment
Practicum Evaluatin Frm - Frmative Assessment Candidate Name: Candidate ID#: Mentr/Principal Name: LEA/District: Cllege/University: Prgram Crdinatr: This frm is t be cmpleted and frmally shared with the
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationStatement of Work for Linked Data Consulting Services
A. Backgrund Infrmatin Statement f Wrk fr Linked Data Cnsulting Services The Natinal Library f Medicine (NLM), in Bethesda, Maryland, is a part f the Natinal Institutes f Health, US Department f Health
More informationCALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP
I. Intrductin CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP The Calvin Jhnsn Jr. Fundatin, Inc. (CJJRF) is a nn-prfit 501(c)(3) rganizatin funded in 2008 by Calvin MEGATRON
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationKessler Foundation West Orange, NJ PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-16-1-0726 TITLE: A Randmized Cntrlled Trial f the Grup-Based Mdified Stry Memry Technique in TBI PRINCIPAL INVESTIGATOR: Nancy D. Chiaravallti, PhD CONTRACTING ORGANIZATION: Kessler
More informationJefferies 2014 Global Healthcare Conference. June 3, 2014
Jefferies 2014 Glbal Healthcare Cnference June 3, 2014 Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s financial results, business prspects and
More informationImproving Surveillance and Monitoring of Self-harm in Irish Prisons
HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationICT4LIFE. Final Conference. ICT4Life field work - tailored solutions in diverse regional context Ariane Girault, E-Seniors Association
ICT4LIFE Final Cnference ICT4Life field wrk - tailred slutins in diverse reginal cntext Ariane Girault, E-Senirs Assciatin 10/22/2018 1 Why a field wrk with users in a research prject? The bjectives f
More informationMalaria 2025: Accelerate to Eliminate The Global Technical Strategy for Malaria: Setting global targets Azra Ghani, GTS Steering Committee
Malaria 2025: Accelerate t Eliminate The Glbal Technical Strategy fr Malaria: 2016-2025 Setting glbal targets Azra Ghani, GTS Steering Cmmittee Geneva, 12 March 2014 1 Visin and Gals Purpse f Visin and
More informationApril 23, 2008 Information Sheet: Safety of BPA-derived Can Liners. Summary
April 23, 2008 Infrmatin Sheet: Safety f BPA-derived Can Liners Summary The use f bisphenl A (BPA)-derived epxy resins t make prtective catings fr metal fd and beverage packaging helps prvide safe, whlesme
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationName: Anchana Ganesh Age: 21 years Home Town: Chennai, Tamil Nadu Degree: B.Com. Profilometer Score. Profilometer Graph
Ms. Archana Ganesh Candidate Analyzed n: August 7 th, 2012 Candidate Infrmatin: Name: Anchana Ganesh Age: 21 years Hme Twn: Chennai, Tamil Nadu Degree: B.Cm Abut Prfilmeter Prfilmeter is a Psychmetric
More informationQUALITY AND SAFETY MEASURES UPDATE January 2016
CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:
More informationWorld Confederation for Physical Therapy Congress , May Singapore
Wrld Cnfederatin fr Physical Therapy Cngress 2015 1-4, May Singapre Call fr applicatins fr Chair f the Internatinal Scientific Cmmittee The Executive Cmmittee f WCPT invites applicatins and suggestins
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationOrganizational Capacity for Change and Patient Safety
Organizatinal Capacity fr Change and Patient Safety Debrah M. Nadzam, PhD, FAAN - Jint Cmmissin Resurces Lrrie Jnes-Hartley, MSN, CRRN-A - Durham Reginal Hspital Presentatin Objectives Briefly describe
More informationResponse to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines
Respnse t type 2 vaccine-derived pliviruses prir t glbal topv withdrawal Interim Guidelines August 2015 GPEI peratinal guidance nte August 2015 Summary Prepare fr prmpt actin fr any area r ppulatin at
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationA Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013
A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationNew Mexico Striving Toward Excellence Program (NM STEP), The Data Scholars Initiative for Child Welfare
2015 New Mexic Striving Tward Excellence Prgram (NM STEP), The Data Schlars Initiative fr Child Welfare YEAR ONE ANNUAL EVALUATION REPORT 2015 LARICIA LONGWORTH-REED THE BUTLER INSTITUTE FOR FAMILIES University
More informationOverview of ICD-10-CM & ICD-10-PCS
Overview f ICD-10-CM & ICD-10-PCS Presented By: Stacey Chevius, BA, AHI, CPC, CDIP AHIMA Apprved ICD-10-CM/PCS Trainer and Ambassadr May 2013 Why ICD-10? ICD-10 cde sets allw prviders t drill dwn int manifestatins
More informationPandemic H1N1 2009: DrillSafe Update. David Blizzard BD Manager, Energy Mining and Infrastructure
Pandemic H1N1 2009: DrillSafe Update David Blizzard BD Manager, Energy Mining and Infrastructure Pandemic H1N1 Update CDC.Gv USA Pandemic H1N1 Summary Pints Virus cntinues t spread with nearly all WHO
More informationA fake medicine that passes itself off as a real, authorised medicine. (1)
Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces
More informationSOLUBLE URANIUM DEFINITION FOR REGULATORY COMPLIANCE
SOLUBLE URANIUM DEFINITION FOR REGULATORY COMPLIANCE Rland Benke, Ph.D., CHP (Center fr Nuclear Waste Regulatry Analyses) Tanya Oxenberg, Ph.D. (U.S. Nuclear Regulatry Cmmissin) James Webb (U.S. Nuclear
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationGeneric Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations
Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationMGPR Training Courses Guide
MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More informationGrant Proposal: Funding a Program Evaluation of the Healing Foods Program at UCSD Moores Cancer Center
Grant Prpsal: Funding a Prgram Evaluatin f the Healing Fds Prgram at UCSD Mres Cancer Center by Viveca Taylr A paper submitted t the faculty f the University f Nrth Carlina at Chapel Hill in partial fulfillment
More informationSummary of Significant Changes. Policy
This Plicy replaces POL229/3 Cpy Number Effective 17/05/17 Summary f Significant Changes Updated survival rates fllwing heart transplantatin. Edited Sectin 6.2 in light f new prcess fr urgent heart-lung
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More information